Title : The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.

Pub. Date : 2016 Oct

PMID : 27367933






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The CD25-binding antibody daclizumab high-yield process (DAC HYP) is an interleukin (IL)-2 signal modulating antibody that shares primary amino acid sequence and CD25 binding affinity with Zenapax , a distinct form of daclizumab, which was approved for the prevention of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids. Cyclosporine interleukin 2 receptor subunit alpha Homo sapiens